Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S . Shareholders who purchased shares of NVO ...
Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...
JPMorgan analysts revised their outlook on Novo Nordisk (NYSE:NVO) stock, reducing the price target to DKK1,000 from DKK1,050. Despite the adjustment, they maintained an Overweight rating on the ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results